Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Other Events
Item8.01
| Other Events. |
On January3, 2017, Inotek Pharmaceuticals Corporation (the
Company) issued a press release announcing the top-line results
of MATrX-1, the first pivotal Phase 3 trial of
trabodenoson for the treatment of primary open-angle
glaucoma or ocular hypertension. The full text of the press
release is filed as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
ExhibitNo. |
Description |
|
| 99.1 |
Press release issued by Inotek Pharmaceuticals Corporation on January 3, 2017, furnished herewith. |
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases. Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Recent Trading Information
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) closed its last trading session 00.00 at 6.10 with 643,125 shares trading hands.
